loading...| Preferred Name |
canakinumab |
|
| Synonyms |
|
|
| ID |
http://purl.obolibrary.org/obo/dinto_DB06168 |
|
| ATCCode |
L04AC08 |
|
| binds | ||
| CASRN |
914613-48-2 |
|
| DBBrand |
ilaris |
|
| DBSynonym |
acz885 acz-885 |
|
| Definition |
Canakinumab is a recombinant, human anti-human-IL-1? monoclonal antibody that belongs to the IgG1/? isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298). Canakinumab binds to human IL-1? and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). Clinical trials have established the administration of canakinumab every 2 weeks to be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist, anakinra, which must be injected daily and which is often poorly tolerated by patients. |
|
| has pharmacological target | ||
| label |
canakinumab |
|
| may interact with |
http://purl.obolibrary.org/obo/CHEBI_2948 http://purl.obolibrary.org/obo/dinto_DB00092 http://purl.obolibrary.org/obo/dinto_DB00108 http://purl.obolibrary.org/obo/dinto_DB06674 http://purl.obolibrary.org/obo/dinto_DB00051 http://purl.obolibrary.org/obo/dinto_DB06372 http://purl.obolibrary.org/obo/dinto_DB00026 http://purl.obolibrary.org/obo/dinto_DB00074 |
|
| prefixIRI |
obo2:dinto_DB06168 |
|
| prefLabel |
canakinumab |
|
| xref |
Drugs.com:http://www.drugs.com/mtm/canakinumab.html National Drug Code Directory:0078-0582-61 Wikipedia:http://en.wikipedia.org/wiki/Canakinumab |
|
| subClassOf |